Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) and Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.
Insider and Institutional Ownership
2.7% of Alpha Tau Medical shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 39.5% of Alpha Tau Medical shares are held by company insiders. Comparatively, 3.0% of Vivos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Alpha Tau Medical and Vivos Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alpha Tau Medical | N/A | N/A | -$29.16 million | ($0.45) | -6.00 |
| Vivos Therapeutics | $14.58 million | 1.50 | -$13.58 million | ($5.68) | -0.65 |
Profitability
This table compares Alpha Tau Medical and Vivos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alpha Tau Medical | N/A | -38.62% | -29.89% |
| Vivos Therapeutics | -86.19% | -335.04% | -93.58% |
Risk & Volatility
Alpha Tau Medical has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.47, indicating that its share price is 647% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and price targets for Alpha Tau Medical and Vivos Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alpha Tau Medical | 0 | 0 | 2 | 0 | 3.00 |
| Vivos Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Alpha Tau Medical currently has a consensus price target of $8.00, indicating a potential upside of 196.30%. Vivos Therapeutics has a consensus price target of $6.30, indicating a potential upside of 69.81%. Given Alpha Tau Medical’s higher possible upside, equities research analysts plainly believe Alpha Tau Medical is more favorable than Vivos Therapeutics.
Summary
Alpha Tau Medical beats Vivos Therapeutics on 6 of the 11 factors compared between the two stocks.
About Alpha Tau Medical
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
